These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim. Piccin A; Amaddii G; Natolino F; Billio A; Cortelazzo S Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s149-50. PubMed ID: 23736912 [No Abstract] [Full Text] [Related]
3. [Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim]. Rodríguez Vargas B; Serna Pérez J; Bermejo Vicedo T Farm Hosp; 2013; 37(3):265-6. PubMed ID: 23789804 [No Abstract] [Full Text] [Related]
4. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura. Atkinson K Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice. Depré F; Aboud N; Mayer B; Salama A PLoS One; 2018; 13(6):e0198184. PubMed ID: 29856800 [TBL] [Abstract][Full Text] [Related]
6. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973 [TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study. Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388 [TBL] [Abstract][Full Text] [Related]
8. New therapeutic options for immune thrombocytopenia. Schipperus M; Fijnheer R Neth J Med; 2011; 69(11):480-5. PubMed ID: 22173361 [TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration. Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314 [No Abstract] [Full Text] [Related]
10. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038 [TBL] [Abstract][Full Text] [Related]
11. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP]. Mori M; Kato M; Koh K; Hanada R Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675 [TBL] [Abstract][Full Text] [Related]
12. Successful treatment of eltrombopag-resistant refractory immune thrombocytopenia with romiplostim. Nakazato T; Ito C; Mihara A; Aisa Y Int J Hematol; 2013 Feb; 97(2):291-3. PubMed ID: 23275229 [No Abstract] [Full Text] [Related]
13. Current treatment options for primary immune thrombocytopenia. Salama A Expert Rev Hematol; 2011 Feb; 4(1):107-18. PubMed ID: 21322783 [TBL] [Abstract][Full Text] [Related]
14. Simultaneous romiplostin, eltrombopag, and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydrocortisone, splenectomy, intravenous IgG, and rituximab. Ruiz-Arguelles GJ; Ruiz-Delgado GJ; Velázquez-Sánchez-de-Cima S; Zamora-Ortiz G Hematology; 2013 May; 18(3):175-7. PubMed ID: 23321502 [TBL] [Abstract][Full Text] [Related]
15. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis. Puavilai T; Thadanipon K; Rattanasiri S; Ingsathit A; McEvoy M; Attia J; Thakkinstian A Br J Haematol; 2020 Feb; 188(3):450-459. PubMed ID: 31423574 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia. Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773 [No Abstract] [Full Text] [Related]
17. New insights and therapeutics for immune-mediated thrombocytopenia. Metjian A; Abrams CS Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):71-84. PubMed ID: 18095908 [TBL] [Abstract][Full Text] [Related]
18. Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim. Sartori R; Candiotto L; Ruggeri M; Tagariello G Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s151-2. PubMed ID: 24120607 [No Abstract] [Full Text] [Related]
19. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview. Vibor M; Rogulj IM; Ostojic SK Cardiovasc Hematol Disord Drug Targets; 2017 Jul; 17(1):38-51. PubMed ID: 28034281 [TBL] [Abstract][Full Text] [Related]
20. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center. González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127 [No Abstract] [Full Text] [Related] [Next] [New Search]